Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus

Journal of Immunology

Volumn 169, Issue 6, 2002, Pages 3208-3216

  Chen, Margaret ^a   Hu, Ke Fei ^a   Rozell, Björn ^a   Örvell, Claes ^a   Morein, Bror ^a   Liljeström, Peter ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; GAMMA INTERFERON; ISCOM; LYSYLTYROSYLLYSYLASPARAGINYLALANYLVALYLTHREONYLGLUTAMYLLEUCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN FG; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELL HYPERPLASIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; IMMUNITY; LUNG DISEASE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPLICON; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SEMLIKI FOREST ALPHAVIRUS; T LYMPHOCYTE; TH2 CELL; VACCINATION; VIRUS ADSORPTION; VIRUS RECOMBINANT; VIRUS RESISTANCE; VIRUS TITRATION;

EID: 0037105524     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.6.3208     Document Type: Article

References (63)

1. RSV and chronic asthma
2. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
3. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine
4. Immune-mediated disease pathogenesis in respiratory syncytial virus infection
5. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology
6. Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins
7. Distinct types of lung disease caused by functional subsets of antiviral T cells
8. Mutant forms of the F protein of human respiratory syncytial (RS) virus induce a cytotoxic T lymphocyte response but not a neutralizing antibody response and only transient resistance to RS virus infection
9. Recent developments in the biology of respiratory syncytial virus: Are vaccines and new treatments just round the corner?
10. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice
11. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type I envelope protein and challenge with a high dose of SHIV-4 virus
12. Recombinant Semliki Forest virus particles encoding the prME or NSI proteins of louping ill virus protect mice from lethal challenge
13. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara
14. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus
15. Interferon production and virus replication in lymphoblastoid cells infected with different viruses
16. γ interferon production and cytotoxicity of spleen cells from mice infected with Semliki Forest virus
17. Expression of IFN A genes in subpopulations of peripheral blood cells
18. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses
19. Immunomodulation by iscoms, immune stimulating complexes
20. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses
21. + T cells during experimental virus infection
22. Preparation and characterization of monoclonal antibodies directed against five structural components of human respiratory syncytial virus subgroup B
23. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon
24. Two-helper RNA system for production of recombinant Semliki forest virus particles
25. Characterization of genotype-specific epitopes of the HN protein of mumps virus
26. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus
27. Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent
28. Protection against respiratory syncytial virus infection by DNA immunization
29. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus
30. Respiratory synctial virus infection in BALB/c mice previously immunized with Formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern
31. + T lymphocytes down-regulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection
32. + T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection
33. Structural homology of the central conserved region of the attachment protein G of respiratory syncytial virus with the fourth subdomain of 55-kDa tumor necrosis factor receptor
34. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus
35. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein
36. + T-cell memory in the respiratory tract
37. + T cell effector mechanisms in resistance to infection
38. Viral clearance without destruction of infected cells during acute HBV infection
39. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
40. Origin, maturation and antigen presenting function of dendritic cells
41. DNA and RNA-based vaccines: Principles, progress and prospects
42. The molecular pathogenesis of Semliki Forest virus: A model virus made useful?
43. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
44. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs
45. Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulatory complexes (iscoms)
46. Initiation of cytotoxic T-cell response and protection of BALB/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine
47. Internalization of iscom-borne antigens and presentation under MHC class I or class II restriction
48. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells
49. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis
50. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: Pathway of presentation and regulation by cytokines
51. Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages
52. Productive infection of isolated human alveolar macrophages by respiratory syncytial virus
53. Antibody-mediated enhancement of respiratory syncytial virus infection in two monocyte/macrophage cell lines
54. Airway goblet cells: Responsive and adaptable front-line defenders
55. Airway goblet cell mucin: Its structure and regulation of secretion
56. IL-13-induced airway hyperreactivity during respiratory syncytial virus infection is STAT6 dependent
57. NIH conference asthma
58. Interleukin-13: Central mediator of allergic asthma
59. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge
60. Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of Formalin-inactivated RSV- or BBG2Na-immunized mice
61. Respiratory syncytial virus predisposes mice to augmented allergic airway responses via IL-13-mediated mechanisms
62. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate